| 温 辉,余青洲,刘 志,王 森,谭 谡.腰痹通胶囊与布洛芬缓释胶囊联合用药治疗慢性腰痛疗效的随机对照研究[J].,2022,(16):3117-3121 |
| 腰痹通胶囊与布洛芬缓释胶囊联合用药治疗慢性腰痛疗效的随机对照研究 |
| Randomized Controlled Study on the Efficacy of Yaobitong Capsule and Ibuprofen Sustained Release Capsule in the Treatment of Chronic Low Back Pain |
| 投稿时间：2022-01-26 修订日期：2022-02-22 |
| DOI：10.13241/j.cnki.pmb.2022.16.024 |
| 中文关键词: 慢性腰痛 腰痹通胶囊 布洛芬缓释胶囊 疗效 炎性因子 |
| 英文关键词: Chronic low back pain Yaobitong capsule Ibuprofen sustained release capsule Efficacy Inflammatory factor |
| 基金项目:重庆市卫生和计划生育委员会资助项目（2016SX002216） |
|
| 摘要点击次数: 492 |
| 全文下载次数: 282 |
| 中文摘要: |
| 摘要 目的：观察腰痹通胶囊与布洛芬缓释胶囊联合用药治疗慢性腰痛的临床疗效。方法：将168例在我院门诊接受治疗的慢性腰痛患者随机分为A组、B组与C组（各56例），A组给予口服腰痹通胶囊 (3粒/次)，3次/d，饭后服药；B组给予布洛芬缓释胶囊治疗 (300 mg/次)，2次/d，饭后口服；C组同时口服腰痹通胶囊和布洛芬缓释胶囊（用法同前），3组均治疗1个疗程。观察治疗前后3组患者的临床疗效、视觉模拟评分（VAS）、Oswestry功能障碍指数（ODI）评分、日本骨科协会腰椎治疗评价量表（JOA）评分、血清炎性因子和药物副作用等各项指标，并进行对比分析。结果：所有患者均完成了研究，没有退出或脱落病例。A组的总有效率为76.79%，B组的总有效率为82.14%，C组的总有效率为96.43%，经统计学分析，AB两组之间没有显著的统计学差异（P>0.05），而C组与A组或B组之间均有显著性差异（P<0.05）。3组的VAS、ODI、JOA评分在治疗前后具有显著的统计学差异（P<0.05），其中C组治疗后的相关评分优于其他两组（P<0.05）。C组患者治疗后的炎性因子包括C反应蛋白(CRP)、白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平均低于A组、B组(P<0.05)。A组的药物副作用最少，B组的药物副作用最多，A组和C组的不良反应发生率低于B组（P<0.05）。结论：腰痹通胶囊联合布洛芬缓释胶囊口服治疗慢性腰痛的疗效明显优于这两种药物单独使用，可缓解患者腰部疼痛，改善腰椎功能，降低血清炎性因子水平。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the clinical efficacy of Yaobitong capsule combined with ibuprofen sustained release capsule in the treatment of chronic low back pain. Methods: 168 patients with chronic low back pain who were treated in the outpatient department of our hospital were randomly divided into group A, group B and group C (56 cases in each group). Group A was given Yaobitong capsule (3 capsules / time), 3 times / d after meals. Group B was treated with ibuprofen sustained release capsule (300mg / time), twice a day, orally after meals. Group C took Yaobitong capsule and ibuprofen sustained release capsule orally at the same time (the usage was the same as before), and the three groups were treated for one course of treatment. The clinical efficacy, visual analogue scale (VAS), Oswestry dysfunction index (ODI) score, Japanese Orthopaedic Association lumbar treatment evaluation scale (JOA) score, serum inflammatory factors and drug side effects of the three groups were observed and compared before and after treatment. Results: All patients completed the study without withdrawal or abscission. The total effective rate in group A was 76.79%, the total effective rate in group B was 82.14%, and the total effective rate in group C was 96.43%, through statistical analysis, there was no significant difference between group A and group B(P>0.05), but there was significant difference between group C and group A or group B(P<0.05). The scores of VAS, ODI and JOA in the three groups had significant statistical differences before and after treatment (P<0.05), and the relevant scores in group C were better than those in the other two groups(P<0.05). The levels of inflammatory factors included C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in group C after treatment were lower than those in group A and group B (P<0.05). Group A had the least drug side effects, and group B had the most drug side effects, the incidence of adverse reactions in group A and group C was lower than that in group B (P<0.05). Conclusion: Yaobitong capsule combined with ibuprofen sustained release capsule is significantly better than the two drugs alone in the treatment of chronic low back pain. It can alleviate patients' low back pain, improve lumbar function and reduce the level of serum inflammatory factors. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
